The regulatory delays stem from the presence of trace levels of a nitrosamine impurity that were initially detected in launch materials for two vonoprazan products from Phathom Pharmaceuticals.
High clarithromycin resistance rates among H pylori isolates in the United States and Europe are grounds for arguing against its use in PPI-based triple therapy, researchers say.